These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 28194654)

  • 21. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.
    Ward A; Bozkaya D; Fleischmann J; Dubois D; Sabatowski R; Caro JJ
    Curr Med Res Opin; 2007 Oct; 23(10):2333-45. PubMed ID: 17697453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation.
    Meissner W; Leyendecker P; Mueller-Lissner S; Nadstawek J; Hopp M; Ruckes C; Wirz S; Fleischer W; Reimer K
    Eur J Pain; 2009 Jan; 13(1):56-64. PubMed ID: 18762438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolonged-release oxycodone/naloxone in nonmalignant pain: single-center study in patients with constipation.
    Gatti A; Casali M; Lazzari M; Tufaro G; Gafforio P; Silvestri C; Marcassa C; Sabato AF
    Adv Ther; 2013 Jan; 30(1):41-59. PubMed ID: 23269562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Opioid use for noncancer pain and risk of myocardial infarction amongst adults.
    Li L; Setoguchi S; Cabral H; Jick S
    J Intern Med; 2013 May; 273(5):511-26. PubMed ID: 23331508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. No pain, no strain: Targin® mitigates pain and constipation following spinal cord injury.
    Sachdeva R; Hosseinzadeh A; Rizzardo A; Maharaj A; Berger M; Krassioukov A
    Ann Clin Transl Neurol; 2023 Mar; 10(3):453-458. PubMed ID: 36692221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The attractiveness of opposites: agonists and antagonists.
    O'Brien T
    J Pain Palliat Care Pharmacother; 2015 Mar; 29(1):67-9. PubMed ID: 25643224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined oral prolonged-release oxycodone and naloxone in chronic pain management.
    Mercadante S; Giarratano A
    Expert Opin Investig Drugs; 2013 Jan; 22(1):161-6. PubMed ID: 23215628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular disorders associated with naloxone monotherapy and in fixed-dose combination with opioids: Data from international safety surveillance.
    Sandhu A; Kao D; Mehler PS; Haigney MC; Krantz MJ
    Int J Cardiol; 2016 Jun; 212():360-3. PubMed ID: 27060723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does tapentadol affect sex hormone concentrations differently from morphine and oxycodone? An initial assessment and possible implications for opioid-induced androgen deficiency.
    Eichenbaum G; Göhler K; Etropolski M; Steigerwald I; Pergolizzi J; Kim M; Vorsanger G
    J Opioid Manag; 2015; 11(3):211-27. PubMed ID: 25985806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The abuse potential of Remoxy(®), an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone.
    Setnik B; Roland CL; Cleveland JM; Webster L
    Pain Med; 2011 Apr; 12(4):618-31. PubMed ID: 21463474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of oxycodone prolonged-release vs. oxycodone + naloxone prolonged-release after laparoscopic hysterectomy.
    Comelon M; Wisloeff-Aase K; Raeder J; Draegni T; Undersrud H; Qvigstad E; Bjerkelund CE; Lenz H
    Acta Anaesthesiol Scand; 2013 Apr; 57(4):509-17. PubMed ID: 23301686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the risks of opioid abuse or dependence between tapentadol and oxycodone: results from a cohort study.
    Cepeda MS; Fife D; Ma Q; Ryan PB
    J Pain; 2013 Oct; 14(10):1227-41. PubMed ID: 23850177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse effects of modified release oxycodone/naloxone in patients with moderate to severe liver impairment.
    Pattullo V; Pattullo GG; Strasser SI
    Med J Aust; 2018 Sep; 209(6):279-280. PubMed ID: 30208822
    [No Abstract]   [Full Text] [Related]  

  • 34. Construction of a Risk Prediction Model of Extended Release Oxycodone Tablet-Induced Nausea and Clarification of Predictive Factors.
    Kumai M; Imai S; Kato S; Koyanagi R; Tsuruga K; Yamada T; Takekuma Y; Sugawara M
    Biol Pharm Bull; 2021; 44(4):593-598. PubMed ID: 33790110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Person-level changes in oxycodone use after the introduction of a tamper-resistant formulation in Australia.
    Schaffer AL; Buckley NA; Degenhardt L; Larance B; Cairns R; Dobbins TA; Pearson SA
    CMAJ; 2018 Mar; 190(12):E355-E362. PubMed ID: 29581162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targinact--opioid pain relief without constipation?
    Drug Ther Bull; 2010 Dec; 48(12):138-41. PubMed ID: 21123290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term efficacy and safety of oxycodone-naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study.
    Guerriero F; Roberto A; Greco MT; Sgarlata C; Rollone M; Corli O
    Drug Des Devel Ther; 2016; 10():1515-23. PubMed ID: 27143857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US.
    Rossiter LF; Kirson NY; Shei A; White AG; Birnbaum HG; Ben-Joseph R; Michna E
    J Med Econ; 2014 Apr; 17(4):279-87. PubMed ID: 24559196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolonged-release naloxone can cause systemic opioid withdrawal.
    Wilcock A
    Eur J Pain; 2009 Oct; 13(9):1001; author reply 1002-3. PubMed ID: 19615925
    [No Abstract]   [Full Text] [Related]  

  • 40. Composite measure to assess efficacy/gastrointestinal tolerability of tapentadol ER versus oxycodone CR for chronic pain: pooled analysis of randomized studies.
    Merchant S; Provenzano D; Mody S; Ho KF; Etropolski M
    J Opioid Manag; 2013; 9(1):51-61. PubMed ID: 23709304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.